Cambridge Cognition Holdings Plc · LSE:COG
Cambridge Cognition — H1 2025 Earnings Presentation
13 slides from Cambridge Cognition's earnings presentation, Sep 3, 2025
Slide 1: Cambridge Cognition H1 2025 Interim Results
2025 Cambridge Cognition H1 2025 Interim Results Date 3 September 2025
Slide 2: Disclaimer
Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE STRICTLY CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, ITS TERRITORIES OR POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND TH
Slide 3: Built on rich, curated data and deep technical expertise
“Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health.” 3 | PRIVATE AND CONFIDENTIAL | © Cambridge Cognition 2025. All rights reserved. www.cambridgec
Slide 4: What Cambridge Cognition Offers
What Cambridge Cognition Offers 3-in-1 Solution A fully configurable product kit Gold standard cognitive testing with validated digital and voice biomarkers for precise Digital & Voice assessments Cognitive Assessments Comprehensive eCOA platform with 1,000+ integrated scales for Our complete platfo
Slide 5: Market Opportunities
Market Opportunities Evidence & • Proven integrated clinical platform • Software as a Service (SaaS) Credibility • End to end service from consultancy, • Collaborations project & data management to • Research consultancy analysis Brand Utility & • Broad application across trial phase & Equity Cli Ap
Slide 6: Business Strategy
Business Strategy Driving cognitive science into clinical impact Trusted Provider in Brain Health Customer Impact Empowered CNS Research Technology Leader Team CNS trials are high risk, costly, and need Industry needs validated digital Sponsors demand efficient, reliable Innovation and execution req
Slide 7: H1 2025 Performance
H1 2025 Performance Interim Financial Results Highlights • New Sales Orders of £6.9m (H1 2024: £3.3m) • Order Book of £16.4m (30 June 2024: £14.6m, 31 December 2024: £13.6m) Key Points • Revenue of £4.3m (H1 2024: £5.6m) • Promised growth in New Sales Orders is being delivered • Adjusted EBITDA loss
Slide 8: H1 2025 Financial Performance
H1 2025 Financial Performance Income Statement Balance Sheet H1 2025 H1 2024 2024 H1 2025 H1 2024 2024 £m £m £m £m £m £m Revenue 4.3 5.6 10.3 Assets Cost of sales (0.9) (1.1) (1.9) Investments 1.8 0.2 1.8 Gross profit 3.4 4.5 8.4 Other non-current assets 6.4 7.3 6.9 Operating expense (4.3) (5.4) (10
Slide 9: Sales >> Order Book >> Revenue
Sales >> Order Book >> Revenue Total Run Off Period Order Book Movement 2025 2025 2026 2027 2028+ Opening Order Book 13.6 6.6 3.6 1.2 2.2 Growing order book with clear success executing focused large pharma commercial strategy, building New Sales Orders 6.9 2.6 2.1 1.4 0.8 long-term relationships &
Slide 10: Continuing to Build Commercial Momentum
Continuing to Build Commercial Momentum Targeted sales strategy to deliver a strong and diversified Order Book Order Book by Customer Order Book by Clinical Trial Phase Clinical Order Book by Disease • Broad Application – >100 active trials and 168 research studies using our technology • Tier-1 Focu
Slide 11: Fundraising
Fundraising • 28 August 2025 announced a fundraising of 4.1m shares at 27.25p per share being a 5% premium to the closing mid-market price to raise £1.1m (before expenses) • Funds will be used to strengthen the balance sheet while the Company pursues sustained profitability and cash flow • Fundraisi
Slide 12: Board Changes
Board Changes Director Role Change Date of change Executive Directors Rob Baker Senior Executive Director & Chief Operating Officer Appointed 28 August 2025 Alex Livingstone-Learmonth Chief Commercial Officer Appointed As soon as practicable Ronald Openshaw Chief Financial Officer & Head of Corporat
Slide 13: Outlook
Outlook Expanding Market Opportunity with Strong Tailwinds • Active CNS market and clinical trial growth • Ageing population and digital adoption drive sustained demand for cognitive assessment solutions • Strategy to address market opportunity in Healthcare and Consumer Execution & Financial Discip
Cambridge Cognition Holdings — H1 2025 Earnings Presentation on 6ix